We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+29.19%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$501M
AUM Growth
+$82.2M
Cap. Flow
-$73.5M
Cap. Flow %
-14.69%
Top 10 Hldgs %
69.75%
Holding
49
New
6
Increased
15
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
EVCM icon
EverCommerce
EVCM
+$16M
2
ENGN icon
enGene Therapeutics
ENGN
+$15M
3
SGMT icon
Sagimet Biosciences
SGMT
+$9.47M
4
BRZE icon
Braze
BRZE
+$5.31M
5
LRMR icon
Larimar Therapeutics
LRMR
+$4.52M

Top Sells

Rank Stock Value
1
TOST icon
Toast
TOST
+$115M
2
KROS icon
Keros Therapeutics
KROS
+$10.7M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$7.97M
4
CGEM icon
Cullinan Oncology
CGEM
+$7.65M
5
BPMC
Blueprint Medicines
BPMC
+$6.63M

Sector Composition

Rank Sector Weight
1 Healthcare 66.92%
2 Financials 17.24%
3 Technology 14.42%
4 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOOD icon
1
Robinhood
HOOD
$77.7B
$54M 10.78%
4,237,409
– –
CGEM icon
2
Cullinan Oncology
CGEM
$1.08B
$49.8M 9.96%
2,924,842
-495,000
-14% -$7.65M
PLRX icon
3
Pliant Therapeutics
PLRX
$65.6M
$44.8M 8.94%
3,004,199
– –
ENGN icon
4
enGene Therapeutics
ENGN
$118M
$41.7M 8.33%
2,461,350
+1,226,590
+99% +$15M
TRML
5
DELISTED
Tourmaline Bio
TRML
$32M 6.39%
1,447,401
+115,099
+9% +$4.06M
OBDC icon
6
Blue Owl Capital
OBDC
$5.36B
$31.5M 6.28%
2,045,070
– –
KVYO icon
7
Klaviyo
KVYO
$5.49B
$30.5M 6.1%
1,198,270
– –
LRMR icon
8
Larimar Therapeutics
LRMR
$398M
$30.3M 6.06%
3,994,468
+580,000
+17% +$4.52M
SLRN
9
DELISTED
ACELYRIN
SLRN
$19.1M 3.81%
2,826,028
+533,038
+23% +$4.05M
EVCM icon
10
EverCommerce
EVCM
$2.15B
$15.5M 3.09%
+1,641,929
New +$16M
RPTX
11
DELISTED
Repare Therapeutics
RPTX
$14.7M 2.94%
3,122,499
– –
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$2.56B
$12.5M 2.5%
268,238
+5,000
+2% +$236K
KROS icon
13
Keros Therapeutics
KROS
$202M
$11.4M 2.28%
172,633
-180,000
-51% -$10.7M
INZY
14
DELISTED
Inozyme Pharma
INZY
$9.73M 1.94%
1,270,027
– –
IRON icon
15
Disc Medicine
IRON
$3.03B
$9.67M 1.93%
155,260
+15,000
+11% +$973K
SGMT icon
16
Sagimet Biosciences
SGMT
$451M
$9.07M 1.81%
1,673,877
+1,318,500
+371% +$9.47M
TOST icon
17
Toast
TOST
$19.1B
$8.04M 1.61%
322,578
-5,567,696
-95% -$115M
ETWO
18
DELISTED
E2open Parent Holdings
ETWO
$7.33M 1.46%
1,650,943
– –
MLYS icon
19
Mineralys Therapeutics
MLYS
$2.31B
$6.99M 1.4%
541,080
-27,299
-5% -$337K
CMPX icon
20
Compass Therapeutics
CMPX
$349M
$5.6M 1.12%
2,829,712
– –
IMA
21
ImageneBio Inc
IMA
$67.2M
$5.53M 1.1%
324,260
+161,459
+99% +$2.94M
MLTX icon
22
MoonLake Immunotherapeutics
MLTX
$1.62B
$5.02M 1%
100,000
+35,000
+54% +$1.9M
DELL icon
23
Dell
DELL
$262B
$4.71M 0.94%
41,245
+6,154
+18% +$574K
OMGA
24
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$3.85M 0.77%
1,055,882
– –
AQST icon
25
Aquestive Therapeutics
AQST
$467M
$3.73M 0.74%
+875,000
New +$2.91M
1
2

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q1 2024 Portfolio in Review

As of Q1 2024, Blue Owl Capital Holdings held 49 positions worth $501M, up 20% from $418M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Blue Owl Capital Holdings withdrew a net $73.5M in Q1 2024, closing 4 positions and reducing 6 holdings. Its most notable exit was Blueprint Medicines, an estimated $6.63M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 67% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in EverCommerce worth $15.5M.

  • Blue Owl Capital Holdings's largest Q1 2024 buy was EverCommerce: 1,641,929 shares worth $15.5M.
  • Blue Owl Capital Holdings added most to enGene Therapeutics in Q1 2024, an estimated $15M increase.
  • Blue Owl Capital Holdings's biggest Q1 2024 reduction was Toast, cutting an estimated $115M.
  • Blue Owl Capital Holdings fully exited Blueprint Medicines in Q1 2024, selling an estimated $6.63M.
  • Blue Owl Capital Holdings's ten largest holdings make up 70% of its $501M portfolio in Q1 2024.
  • Blue Owl Capital Holdings opened 6 new positions and closed 4 in Q1 2024.
  • Blue Owl Capital Holdings's portfolio value rose 20% quarter-over-quarter to $501M.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2024, filed 15 May 2024.